Bioregenx (BRGX) Operating Expenses (2022 - 2026)

Bioregenx's Operating Expenses history runs 5 years deep, the most recent figure standing at $398052.0 for Q1 2026.

• On a quarterly basis, Operating Expenses fell 33.51% year-over-year to $398052.0 in Q1 2026; TTM through Mar 2026 was $2.5 million, a 88.18% decrease from a year earlier, with the FY2025 full-year figure at $2.7 million, down 88.75% from the prior year.
• Operating Expenses fell to $398052.0 in Q1 2026 per BRGX's latest filing, from $1.3 million in the prior quarter.
• Across five years, Operating Expenses topped out at $18.6 million in Q4 2024 and bottomed at $13474.0 in Q3 2022.
• The 5-year median for Operating Expenses is $598646.0 (2025), against an average of $2.0 million.
• Across the five-year window, Operating Expenses jumped 22460.15% in 2023 and plunged 93.27% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $14449.0 in 2022, then soared by 3980.42% to $589580.0 in 2023, then jumped by 3061.5% to $18.6 million in 2024, then plunged by 93.27% to $1.3 million in 2025, then plunged by 68.27% to $398052.0 in 2026.
• Per Business Quant, the three latest BRGX Operating Expenses figures stand at $398052.0 (Q1 2026), $1.3 million (Q4 2025), and $434856.0 (Q3 2025).